Terrorist Attacks Have No Impact on DIA EuroMeeting
The EuroMeeting and Clinical Forum will take place in Paris as planned, in spite of January’s terrorist attacks in the French capital.
The EuroMeeting and Clinical Forum will take place in Paris as planned, in spite of January’s terrorist attacks in the French capital, according to the Drug Information Association (DIA).
“We are working closely with the venue and the city of Paris to make sure all security measures are taken and onsite security will be reinforced,” noted Natacha Scholl, Team Leader of Operations for DIA in Europe, Middle East & Africa. “We will put everything in place to reassure participants of course.”
She does not anticipate that the attacks will have any great impact on delegate numbers. “Registrations haven't stopped over the past days, despite the tragic events,” she remarked.
As of January 15, there were already more than 650 registered participants, and Scholl said the organizers are expecting at least 2500 to 3000 attendees in total for the two events.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
